The stock must drop to account for the dividend earned today. So $0.41 of the drop today is just the dividend earned today. You'll get it back when it hits your account March 2nd.
Let's squeeze the shorts until they have margin calls and are forced to sell other holding to buy UAN at a huge loss. It is what all those stock manipulators deserve trying to make money off their unethical ways.
Let's squeeze the shorts until they have margin calls and are forced to sell other holding to buy TRN at a huge loss. It is what all those stock manipulators deserve trying to make money off their unethical ways.
I bought my shares 2 years ago at $11.30 abd $11.70 and have picked up almost 400 shares since then re-investing dividends giving me a total of 5000 shares. I would love to see the stock soar with the Brazilian expansion and then possibly taken over by one of the major testing lab companies. Their patented hair follicle drug testing is faster and cheaper than anything on the market.
Been collecting a very nice 4% dividend for several years and watched this stock go from $12 to $16. Soon, the expansion in Brazil will start adding additional cash and profits to this company's bottom line and then it will be a buy at $20.
AbbVie Inc. (NYSE: ABBV) was started as Sell at Citigroup.
Read more: Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More - Alcoa, Inc. (NYSE:AA) - 24/7 Wall St. http://247wallst.com/investing/2015/02/09/top-analyst-upgrades-and-downgrades-abbvie-alcoa-apple-deckers-dish-pfizer-petrobras-and-more/#ixzz3RIb2WA4i
Follow us: @247wallst on Twitter | 247wallst on Facebook
The Federal Highway Administration said on Friday that maybe there isn't a problem with Trinity end terminals. The agency had ordered a new round of eight crash tests in the wake of the humongous Texas fraud verdict. Data from the first four of those, assessing 27¾-inch rails, by far the most common variety, show that the Trinity gear "meets the applicable crash test criteria," the FHWA said in a prepared statement. The agency has more testing to do before giving Trinity a clean report card. But the preliminary results don't suggest a scourge of killer guardrails.
Texas A&M Transportation Institute, which designed the technology Trinity uses, released a separate statement calling the ET-Plus "a safe, effective roadside safety product." Referring to all eight federally mandated tests, the latter four of which the government hasn't yet formally analyzed, the university research arm said: "It should be especially noted that in each of the eight tests, no guardrail speared the cabin of the vehicle, nor did any vehicle roll over—two key measures in determining success in such testing."
Trinity itself issued a muted press release reiterating its contention that "when installed, maintained, and impacted within" relevant standards, the ET-Plus functions as required.
Every big company starts as small company. Do you think Google, Facebook, Microsoft, Yahoo, Netflix had reasonable P/E ratios during their first few years doing business. Please take your money and go invest in utilities or telecom companies with their low P/Es and I will stick with game changing high growth companies like this one. If you can't stand the heat, get out of the kitchen.
P/E matters for a stable company, but you can't use P/E to value a stock that has year or year growth of 90% like ILMN reported this quarter. Once it matures a little, then start using measures like P/E. By your logic, a start up that is losing money, but is growing revenue hands over fist, would be worth zero because it had no earnings. The value of any company is based on what people expect the company to make in the long run, not next quarter.
I guess you don't follow the news much for this company. First, the guard rail study done by the not impartial former royalty collecting engineer hired by the plaintiff, has been completely discredited by 4 (count'em 4) impartial engineering experts. Second, the re-testing for the NHSA so far has been 100% perfect. Third, most legal experts expected the faulty jury verdict to be overturned even before this new evidence. There was no fraudulent reimbursement for the guardrails from the feds because the guardrails had an unbroken chain of certification by the fed, this from the feds themselves. The idiot that brought the lawsuit, on behalf of the feds (feds were not a party to the suit) lost his business when Trinity successfully sued him for manufacturing and selling copies of their guardrails. He is just a sore loser and they will never have to pay this verdict.
The Bloomberg article was poorly written but is actually details the faulty methodology of the initial study written by the plaintiff's expert witness. The article switches from talking about the review of the study to the study itself and at one point refers to the study as a review but uniformly states that all four authors of the review dismiss the plaintiff's study as flawed by form and therefore by conclusion.
Unfortunately, the elephant in the room is sub $50 per barrel oil which has a bigger impact on their main businesses. Oil will eventually recover, and when it does, there will no longer be the threat of lawsuits hanging over the guard rail,business. So the debunking of the faulty guard rail study, combined with perfect results from the first half of the re-testing of their guard rails under the watchful eyes of the FHWA will be be long term positive news events for Trinity.
A study linking deadly highway crashes to a Trinity Industries Inc. (TRN) guardrail system was found to have fundamental flaws by independent reviewers brought in after states banned the safety devices.
The independent review made public today questions the validity of that study, faulting its methodology and its conclusions, which were called “inappropriate” and “questionable.”
The review of the study comes as lawmakers press the Federal Highway Administration, which vets the safety of highway devices, for more stringent crash testing of the Trinity device. About 200,000 ET-Plus systems are installed in the U.S., the agency has said.
Last month, the federal agency made a public call for information on accidents involving Trinity’s ET-Plus guardrail system, which lawsuits have tied to at least eight deaths. Crash survivors have claimed that the ET-Plus can lock up when hit, piercing cars instead of giving way as intended.
The review consists of four separate reports, each written by an engineering professor without ties to the guardrail industry, according to the FHWA. All four reviewers said the study didn’t account for key variables that could affect the crashworthiness of a guardrail system, such as the nearby traffic volume, speed limit and other road conditions.
Why would a Co. build new plant when they could have purchased CVR partners and got their plant for a huge discount vs. building a new plant? Margins on fertilizer are very bad, so it puzzles me that a company would choose this time to spend $2B to enter this market. What am I missing?
How can Express Scripts dictate to doctors what they can prescribe? The doctors are the ones on the hook for malpractice if something goes wrong. So if patients don't get cured or suffer huge side effects, is the doctor off the hook since he had originally prescribed Harvoni? IMHO, this only makes sense if the drugs were equivalent in efficacy and side effects. Abbvie HCV drugs are not as effective for the majority lf the HCV genotypes. This was a bad day for GLD longs and patients with HCV.